Aiping Zhou

1.3k total citations
28 papers, 133 citations indexed

About

Aiping Zhou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Aiping Zhou has authored 28 papers receiving a total of 133 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 10 papers in Surgery. Recurrent topics in Aiping Zhou's work include Renal cell carcinoma treatment (8 papers), Gastric Cancer Management and Outcomes (7 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Aiping Zhou is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Gastric Cancer Management and Outcomes (7 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Aiping Zhou collaborates with scholars based in China, United States and Australia. Aiping Zhou's co-authors include Jinwan Wang, Wen Zhang, Yongkun Sun, Dafang Zhong, Haoyuan Jiang, Chengxu Cui, Donghua Lou, Qiong Qin, Xiaoyan Chen and Jianzhong Shou and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Aiping Zhou

21 papers receiving 131 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aiping Zhou China 7 79 54 35 26 25 28 133
I. Boukovinas Greece 7 132 1.7× 89 1.6× 31 0.9× 54 2.1× 45 1.8× 14 170
Lijian Xia China 8 44 0.6× 88 1.6× 49 1.4× 19 0.7× 68 2.7× 19 190
Mercè Barenys Spain 5 88 1.1× 54 1.0× 50 1.4× 25 1.0× 38 1.5× 11 170
Rubén Dario Kowalyszyn United States 8 136 1.7× 133 2.5× 49 1.4× 15 0.6× 12 0.5× 24 194
Tracy Jiezhen Loh Singapore 5 66 0.8× 93 1.7× 20 0.6× 9 0.3× 70 2.8× 9 160
Philipp Schüler Germany 7 68 0.9× 59 1.1× 17 0.5× 75 2.9× 85 3.4× 9 159
Eduardo Cronemberger Brazil 7 61 0.8× 48 0.9× 14 0.4× 9 0.3× 14 0.6× 15 94
Nikhil Pande India 10 132 1.7× 134 2.5× 33 0.9× 9 0.3× 54 2.2× 30 227
N. C. Tebbutt Australia 8 69 0.9× 125 2.3× 26 0.7× 14 0.5× 32 1.3× 17 173
Tomokazu Hisayuki Japan 7 94 1.2× 140 2.6× 18 0.5× 23 0.9× 76 3.0× 20 186

Countries citing papers authored by Aiping Zhou

Since Specialization
Citations

This map shows the geographic impact of Aiping Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aiping Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aiping Zhou more than expected).

Fields of papers citing papers by Aiping Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aiping Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aiping Zhou. The network helps show where Aiping Zhou may publish in the future.

Co-authorship network of co-authors of Aiping Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Aiping Zhou. A scholar is included among the top collaborators of Aiping Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aiping Zhou. Aiping Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yu, Xianjun, Jieer Ying, Enxiao Li, et al.. (2025). Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.. Journal of Clinical Oncology. 43(16_suppl). 4017–4017. 2 indexed citations
3.
4.
5.
Wu, Jie, et al.. (2024). High Expression of Cancer-derived Immunoglobulin G is Associated with Poor Survival in Metastatic Clear Cell Renal Cell Carcinoma. European Urology Open Science. 61. 56–58. 1 indexed citations
6.
Dong, Xiying, Gang Song, Tie Wang, et al.. (2023). Clinical practice guideline on bladder cancer (Part II). 1(3). 95–104.
7.
8.
Zhang, Xiaojie, Chunguang Guo, Yingtai Chen, et al.. (2021). [Prognosis and Related Factors of Patients with Pathological Complete Response after Neoadjuvant Therapy for Gastric Cancer].. PubMed. 43(4). 571–578. 3 indexed citations
9.
10.
Liu, Xiaoqi, Wei Zheng, Li Wen, et al.. (2020). PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy. Urologic Oncology Seminars and Original Investigations. 39(1). 78.e9–78.e16. 5 indexed citations
11.
12.
Chen, Yingtai, Lulu Zhao, Xiaojie Zhang, et al.. (2020). The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study. Journal of Cancer. 12(2). 379–386. 9 indexed citations
13.
Sun, Yongkun, Lin Yang, Chengfeng Wang, et al.. (2017). Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection. Oncotarget. 8(43). 75186–75194. 5 indexed citations
14.
15.
Song, Yan, Chunxia Du, Wen Zhang, et al.. (2016). Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Urologic Oncology Seminars and Original Investigations. 34(6). 258.e15–258.e22. 8 indexed citations
16.
Qin, Qiong, Jianming Ying, Ning Lyu, et al.. (2014). [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].. PubMed. 36(11). 844–8. 1 indexed citations
17.
Du, Feng, Yongkun Sun, Yan Song, et al.. (2013). [Neuroendocrine tumors: analysis of 252 cases].. PubMed. 35(1). 67–70. 3 indexed citations
18.
Zhou, Aiping, Wen Zhang, Xiaoyan Chen, et al.. (2013). Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemotherapy and Pharmacology. 72(5). 1043–1053. 36 indexed citations
19.
Wang, Jinwan, Yihebali Chi, Zhaoxu Zheng, et al.. (2012). Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer.. Journal of Clinical Oncology. 30(15_suppl). e14668–e14668. 7 indexed citations
20.
Zhou, Jinming, et al.. (1997). [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].. PubMed. 19(6). 460–2. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by I. Boukovinas Breakdown of academic impact, for papers by Lijian Xia Breakdown of academic impact, for papers by Mercè Barenys Breakdown of academic impact, for papers by Rubén Dario Kowalyszyn Breakdown of academic impact, for papers by Tracy Jiezhen Loh Breakdown of academic impact, for papers by Philipp Schüler Breakdown of academic impact, for papers by Eduardo Cronemberger Breakdown of academic impact, for papers by Nikhil Pande Breakdown of academic impact, for papers by N. C. Tebbutt Breakdown of academic impact, for papers by Tomokazu Hisayuki
Rankless by CCL
2026